Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-CLI: JVS-100 in Critical Limb Ischemia
NCT01410331Phase 2Completed
- Sponsor
- Juventas Therapeutics
- Start
- Mar 2012
- Primary completion
- Jul 2014
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 2
01
Overview
A Phase 2 trial of JVS-100 in critical limb ischemia (CLI), sponsored by Juventas Therapeutics. Started Mar 2012; status: completed.
02
Drugs
JVS-100
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT01410331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01410331.